Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 7672 results

  1. Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288]

    In development [GID-TA11398] Expected publication date: 30 October 2024

  2. Avapritinib for treating advanced systemic mastocytosis ID3770

    In development [GID-TA11382] Expected publication date: 06 November 2024

  3. Menopause: diagnosis and management

    In development [GID-NG10241] Expected publication date: 07 November 2024

  4. Asthma: diagnosis, monitoring and chronic asthma management

    In development [GID-NG10186] Expected publication date: 27 November 2024

  5. Endometriosis: diagnosis and management - diagnosing endometriosis

    In development [GID-NG10392] Expected publication date: 11 November 2024

  6. Urinary Tract Infection (recurrent): antimicrobial prescribing

    In development [GID-NG10422] Expected publication date: 13 November 2024

  7. Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]

    In development [GID-TA11436] Expected publication date: 13 November 2024

  8. Elafibranor for treating primary biliary cholangitis [ID6331]

    In development [GID-TA11378] Expected publication date: 13 November 2024

  9. Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (Review of TA869) [ID6333]

    In development [GID-TA11418] Expected publication date: 13 November 2024

  10. Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction

    In development [GID-IPG10353] Expected publication date: 14 November 2024

  11. Suspected neurological conditions: recognition and referral (NG127)

    This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

  12. Improving outcomes in urological cancers (CSG2)

    This guideline covers how healthcare services for people with urological cancer should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.

  13. Improving outcomes in breast cancer (CSG1)

    This guideline covers how healthcare services for breast cancer should be organised. It aims to improve care for women with breast cancer by recommending which healthcare professionals should be involved in care.

  14. Improving outcomes for people with brain and other central nervous system tumours (CSG10)

    This guideline covers how healthcare services for people with brain tumours and other central nervous system tumours should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.

  15. Improving outcomes in children and young people with cancer (CSG7)

    This guideline covers how healthcare services for children and young people with cancer should be organised. It aims to improve care by recommending which healthcare professionals should be involved and the types of hospital or cancer centre best suited to provide the care.